



caprotec bioanalytics and Merck KGaA Sign Collaboration Agreement

Berlin, Germany, May 28, 2008 – caprotec bioanalytics GmbH announced today that they have signed a collaboration agreement with Merck KGaA acting for its division Merck Serono.

Under the terms of the agreement caprotec will apply its Capture Compound Mass Spectrometry™ (CCMS) Technology to identify relevant protein – drug molecule interactions for one of Merck Serono’s research projects.

caprotec will receive research funding and potential milestone payments on product development. Further financial details of the agreement were not disclosed.

“The collaboration with Merck Serono is an important milestone for caprotec. Merck Serono is a leader and innovator in the field, and this collaboration validates our capabilities for the development of improved small molecules.” says caprotec’s COO Mathias Grote. “Being able to collaborate with such an established player in this field provides an important further endorsement of our technology in the pharmaceutical industry”.



About caprotec bioanalytics GmbH

caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry™ (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.

caprotec bioanalytics was founded in 2006 by Prof. Dr. Hubert Köster, a long-experienced innovator and serial entrepreneur in the field of biotech. His track records include the foundation of Biosyntech, the first biotech company in Germany, the co-foundation of Milligen/Biosearch and the foundation of Sequenom Inc. As CEO and President of Sequenom he was responsible for one of the most successful US biotech IPOs at the NASDAQ.

After closing a financing round of EUR 6 million caprotec bioanalytics started operations in January 2008 in Berlin-Adlershof. The company is supported by an international scientific advisory board including one Nobel Laureate.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements.

For further information please contact:

caprotec bioanalytics GmbH
Corporate Communications
Tel.: +49 (0)30-6392-3990
info@caprotec.com
www.caprotec.com